Download PDF
Semin Respir Crit Care Med 2003; 24(5): 607-618
DOI: 10.1055/s-2004-815608
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Diffuse Panbronchiolitis

Shoji Kudoh1 , Naoto Keicho2
  • 1Fourth Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
  • 2Department of Respiratory Diseases, Research Institute, International Medical Center of Japan, Toyama, Shinyuku-ku, Tokyo, Japan
Further Information

Publication History

Publication Date:
15 January 2004 (online)

    Permissions and Reprints

ABSTRACT

Diffuse panbronchiolitis (DPB) was first distinguished from chronic obstructive pulmonary diseases in the early 1960s and recorded as a new clinicopathologic entity. This disease affects East Asians for the major part, and is characterized by chronic sinobronchial infection together with diffuse bilateral micronodular pulmonary lesions consisting of inflammatory cells. The prognosis at an advanced stage would often be bleak, where superinfection with Pseudomonas aeruginosa had occurred. Beginning with an initial success of erythromycin therapy, considerable improvement has been achieved in the prognosis of this disease. Simple bactericidal activity of macrolides is not a determinant factor for the clinical effect. An in-depth study, together with its pathogenesis, has been performed to clarify the underlying mechanism. Inhibitions of excessive mucus and water secretion from airway epithelium, neutrophil accumulation in the large airway, lymphocyte and macrophage accumulation around the small airway, and modulation of bacterial virulence have so far been proposed as possible mechanisms.

KEYWORDS

Macrolides - chronic airway infection

REFERENCES

  • 1 Honma H. Diffuse panbronchiolitis [in Japanese].  Nihon Kyobu Shikkan Gakkai Zasshi . 1975;  13 383-395
    PubMedGoogle Scholar
  • 2 Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis [in Japanese].  Naika . 1969;  23 442-451
    PubMedGoogle Scholar
  • 3 Izumi T, Doi O, Nobechi A. et al .Nation-wide survey of diffuse panbronchiolitis [author's transl] [in Japanese]. Annual Report on the study of interstitial lung disease in 1982. Tokyo:.Grant-in Aid from the Ministry of Health and Welfare of Japan; 1983: 3-41
    Google Scholar
  • 4 Homma H, Yamanaka A, Tanimoto S. et al . Diffuse panbronchiolitis: a disease of the transitional zone of the lung.  Chest . 1983;  83 63-69
    CrossrefPubMedGoogle Scholar
  • 5 Kudoh S, Uetake T, Hagiwara K. et al . Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis [in Japanese].  Nihon Kyobu Shikkan Gakkai Zasshi . 1987;  25 632-642
    PubMedGoogle Scholar
  • 6 Homma H. Diffuse panbronchiolitis.  Jpn J Med . 1986;  25 329-334
    PubMedGoogle Scholar
  • 7 Kim Y W, Han S K, Shim Y S. et al . The first report of diffuse panbronchiolitis in Korea: five case reports.  Intern Med . 1992;  31 695-701
    PubMedGoogle Scholar
  • 8 Chu Y C, Yeh S Z, Chen C L, Chen C Y, Chang C Y, Chiang C D. Diffuse panbronchiolitis: report of a case.  J Formos Med Assoc . 1992;  91 912-915
    PubMedGoogle Scholar
  • 9 Tredaniel J, Cazals-Hatem D, Zalcman G, d'Agay M F, Capron F. Diffuse panbronchiolitis: efficacy of low-dose erythromycin.  Respir Med . 1994;  88 479-480
    PubMedGoogle Scholar
  • 10 Homer R J, Khoo L, Smith G J. Diffuse panbronchiolitis in a Hispanic man with travel history to Japan.  Chest . 1995;  107 1176-1178
    CrossrefPubMedGoogle Scholar
  • 11 Hu H, Liu Y, Cai Z, Chen L. A case of diffuse panbronchiolitis.  Chin Med J (Engl) . 1996;  109 949-952
    PubMedGoogle Scholar
  • 12 Zainudin B M, Roslina A M, Fadilah S A, Samad S A, Sufarlan A W, Isa M R. A report of the first three cases of diffuse panbronchiolitis in Malaysia.  Med J Malaysia . 1996;  51 136-140
    PubMedGoogle Scholar
  • 13 Wang H, Sun T, Miao J, Li Y. A definite case of diffuse panbronchiolitis diagnosed by open lung biopsy.  Chin Med J (Engl) . 1998;  111 864
    PubMedGoogle Scholar
  • 14 Tsang K W, Ooi C G, Ip M S. et al . Clinical profiles of Chinese patients with diffuse panbronchiolitis.  Thorax . 1998;  53 274-280
    PubMedGoogle Scholar
  • 15 Poh S C, Wang Y T, Wang W Y. Diffuse panbronchiolitis: a case report.  Singapore Med J . 2001;  42 271-274
    PubMedGoogle Scholar
  • 16 Randhawa P, Hoagland M H, Yousem S A. Diffuse panbronchiolitis in North America: report of three cases and of the literature.  Am J Surg Pathol . 1991;  15 43-47
    CrossrefPubMedGoogle Scholar
  • 17 Poletti V, Patelli M, Poletti G, Bertanti T, Spiga L. Diffuse panbronchiolitis observed in an Italian male.  Sarcoidosis . 1992;  9 67-69
    PubMedGoogle Scholar
  • 18 Fitzgerald J E, King Jr E T, Lynch D A, Tuder R M, Schwarz M I. Diffuse panbronchiolitis in the United States.  Am J Respir Crit Care Med . 1996;  154(2 Pt 1) 497-503
    CrossrefPubMedGoogle Scholar
  • 19 Schulte W, Szrepka A, Bauer P C, Guzman J, Costabel U. Diffuse panbronchiolitis: a rare differential diagnosis of chronic obstructive lung disease [in German].  Dtsch Med Wochenschr . 1999;  124 584-588
    PubMedGoogle Scholar
  • 20 Chantarotorn S, Palwatwichai A, Vattanathum A, Tantamacharik D. Diffuse panbronchiolitis, the first case reports in Thailand.  J Med Assoc Thai . 1999;  82 833-838
    PubMedGoogle Scholar
  • 21 Gulhan M, Erturk A, Kurt B. et al . Diffuse panbronchiolitis observed in a white man in Turkey.  Sarcoidosis Vasc Diffuse Lung Dis . 2000;  17 292-296
    PubMedGoogle Scholar
  • 22 Claxton S, Markos J. A case of diffuse panbronchiolitis.  Aust N Z J Med . 2000;  30 99-100
    PubMedGoogle Scholar
  • 23 Martinez J A, Guimaraes S M, Ferreira R G, Pereira C A. Diffuse panbronchiolitis in Latin America.  Am J Med Sci . 2000;  319 183-185
    CrossrefPubMedGoogle Scholar
  • 24 Fisher Jr S M, Rush W L, Rosado-de-Christenson M L. et al . Diffuse panbronchiolitis: histologic diagnosis in unsuspected cases involving North American residents of Asian descent.  Arch Pathol Lab Med . 1998;  122 156-160
    PubMedGoogle Scholar
  • 25 Brugiere O, Milleron B, Antoine M, Carette M F, Philippe C, Mayaud C. Diffuse panbronchiolitis in an Asian immigrant.  Thorax . 1996;  51 1065-1067
    CrossrefPubMedGoogle Scholar
  • 26 Corne J. Diffuse panbronchiolitis: a new Japanese export?.  Lancet . 1996;  348 1465-1466
    CrossrefPubMedGoogle Scholar
  • 27 Sugiyama Y, Kudoh S, Maeda H, Suzaki H, Takaku F. Analysis of HLA antigens in patients with diffuse panbronchiolitis.  Am Rev Respir Dis . 1990;  141 1459-1462
    CrossrefPubMedGoogle Scholar
  • 28 Keicho N, Tokunaga K, Nakata K. et al . Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis.  Am J Respir Crit Care Med . 1998;  158 846-850
    CrossrefPubMedGoogle Scholar
  • 29 Park M H, Kim Y W, Yoon H I. et al . Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients.  Am J Respir Crit Care Med . 1999;  159 526-529
    CrossrefPubMedGoogle Scholar
  • 30 Keicho N, Ohashi J, Tamiya G. et al . Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis.  Am J Hum Genet . 2000;  66 501-507
    CrossrefPubMedGoogle Scholar
  • 31 Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West.  Thorax . 1994;  49 531-532
    PubMedGoogle Scholar
  • 32 Akai S, Okayama H, Shimura S, Tanno Y, Sasaki H, Takishima T. Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan.  Am Rev Respir Dis . 1992;  146 781-783
    PubMedGoogle Scholar
  • 33 Ichikawa Y, Ninomiya H, Koga H. et al . Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients.  Am Rev Respir Dis . 1992;  146 196-203
    PubMedGoogle Scholar
  • 34 Kadota J, Sakito O, Kohno S. et al . A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis.  Am Rev Respir Dis . 1993;  147 153-159
    PubMedGoogle Scholar
  • 35 Yoshimura K, Iizuka S, Anzai C. et al . Diffuse panbronchiolitis is closely associated with mutations of the CFTR gene.  Am J Respir Crit Care Med . 2000;  161 A77
    PubMedGoogle Scholar
  • 36 Sugiyama Y, Kudoh S, Kitamura S. A case of the bare lymphocyte syndrome with clinical manifestations of diffuse panbronchiolitis [in Japanese].  Nihon Kyobu Shikkan Gakkai Zasshi . 1989;  27 980-983
    PubMedGoogle Scholar
  • 37 Donato L, de la Salle H, Hanau D. et al . Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis.  J Pediatr . 1995;  127 895-900
    PubMedGoogle Scholar
  • 38 Teisserenc H, Schmitt W, Blake N. et al . A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway.  Immunol Lett . 1997;  57 183-187
    CrossrefPubMedGoogle Scholar
  • 39 Furukawa H, Murata S, Yabe T. et al . Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome.  J Clin Invest . 1999;  103 755-758
    PubMedGoogle Scholar
  • 40 Raghavan M. Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome.  J Clin Invest . 1999;  103 595-596
    PubMedGoogle Scholar
  • 41 Azuma A, Keicho N, Furukawa H, Yabe T, Kudoh S. Prolonged survival of a bare lymphocyte syndrome type I patient with diffuse panbronchiolitis treated with erythromycin.  Sarcoidosis Vasc Diffuse Lung Dis . 2001;  18 312-313
    PubMedGoogle Scholar
  • 42 Maeda M, Saiki S, Yamanaka A. Serial section analysis of the lesions in diffuse panbronchiolitis.  Acta Pathol Jpn . 1987;  37 693-704
    PubMedGoogle Scholar
  • 43 Iwata M, Colby T V, Kitaichi M. Diffuse panbronchiolitis: diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations.  Hum Pathol . 1994;  25 357-363
    CrossrefPubMedGoogle Scholar
  • 44 Sato A, Chida K, Iwata M, Hayakawa H. Study of bronchus-associated lymphoid tissue in patients with diffuse panbronchiolitis.  Am Rev Respir Dis . 1992;  146 473-478
    PubMedGoogle Scholar
  • 45 Mukae H, Kadota J, Kohno S. et al . Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis.  Am J Respir Crit Care Med . 1995;  152 613-618
    PubMedGoogle Scholar
  • 46 Ichikawa Y, Koga H, Tanaka M, Nakamura M, Tokunaga N, Kaji M. Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis.  Chest . 1990;  98 917-923
    PubMedGoogle Scholar
  • 47 Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis.  Chest . 1994;  106 1116-1123
    PubMedGoogle Scholar
  • 48 Oda H, Kadota J, Kohno S, Hara K. Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis.  Chest . 1995;  108 116-122
    PubMedGoogle Scholar
  • 49 Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin-1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy.  Respiration . 1996;  63 42-48
    PubMedGoogle Scholar
  • 50 Oishi K, Sonoda F, Kobayashi S. et al . Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases.  Infect Immun . 1994;  62 4145-4152
    PubMedGoogle Scholar
  • 51 Kusano S, Kadota J, Kohno S. et al . Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease.  Respiration . 1995;  62 217-222
    PubMedGoogle Scholar
  • 52 Beringer P M. New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis.  Curr Opin Pulm Med . 1999;  5 371-377
    CrossrefPubMedGoogle Scholar
  • 53 Konstan M W. Therapies aimed at airway inflammation in cystic fibrosis.  Clin Chest Med . 1998;  19 505-513
    CrossrefPubMedGoogle Scholar
  • 54 Akira M, Kitatani F, Lee Y S. et al . Diffuse panbronchiolitis: evaluation with high-resolution CT.  Radiology . 1988;  168 433-438
    PubMedGoogle Scholar
  • 55 Nishimura K, Kitaichi M, Izumi T, Itoh H. Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings.  Radiology . 1992;  184 779-785
    PubMedGoogle Scholar
  • 56 Hansell D M. Small airways diseases: detection and insights with computed tomography.  Eur Respir J . 2001;  17 1294-1313
    CrossrefPubMedGoogle Scholar
  • 57 Takizawa H, Tadokoro K, Miyoshi Y. et al . Serological characterization of cold agglutinin in patients with diffuse panbronchiolitis [in Japanese].  Nihon Kyobu Shikkan Gakkai Zasshi . 1986;  24 257-263
    PubMedGoogle Scholar
  • 58 Koyama H, Nishimura K, Mio T, Ikeda A, Sugiura N, Izumi T. Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis.  Thorax . 1994;  49 540-544
    PubMedGoogle Scholar
  • 59 Nakata K. Revision of clinical guidelines for DPB [author's transl] [in Japanese]. Annual Report on the study of diffuse lung disease in 1998. Tokyo:Grant-in Aid from the Ministry of Health and Welfare of Japan; 1999: 109-111
    Google Scholar
  • 60 Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long-term chemotherapy with erythromycin in chronic lower respiratory tract infections-first report: comparison with amoxicillin [in Japanese].  Kansenshogaku Zasshi . 1986;  60 37-44
    PubMedGoogle Scholar
  • 61 Yamamoto M, Kondo A, Tamura M, Izumi T, Ina Y, Noda M. Long-term therapeutic effects of erythromycin and newquinolone antibacterial agents on diffuse panbronchiolitis [in Japanese].  Nihon Kyobu Shikkan Gakkai Zasshi . 1990;  28 1305-1313
    PubMedGoogle Scholar
  • 62 Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis.  Respiration . 1991;  58 145-149
    PubMedGoogle Scholar
  • 63 Fujii T, Kadota J, Kawakami K. et al . Long-term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection.  Thorax . 1995;  50 1246-1252
    PubMedGoogle Scholar
  • 64 Yamada G, Igarashi T, Itoh E, Tanaka H, Sekine K, Abe S. Centrilobular nodules correlate with air trapping in diffuse panbronchiolitis during erythromycin therapy.  Chest . 2001;  120 198-202
    CrossrefPubMedGoogle Scholar
  • 65 Ichikawa Y, Hotta M, Sumita S, Fujimoto K, Oizumi K. Reversible airway lesions in diffuse panbronchiolitis: detection by high-resolution computed tomography.  Chest . 1995;  107 120-125
    PubMedGoogle Scholar
  • 66 Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow-up CT examination.  Radiology . 1993;  189 559-562
    PubMedGoogle Scholar
  • 67 Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long-term chemotherapy with erythromycin in chronic lower respiratory tract infections-second report: including cases with Pseudomonas infections [in Japanese].  Kansenshogaku Zasshi . 1986;  60 45-50
    PubMedGoogle Scholar
  • 68 Yamamoto M. A double-blind placebo-controlled study on the therapeutic effect of erythromycin on DPB [author's transl.] [in Japanese]. Annual Report on the study of diffuse lung disease in 1990 [in Japanese] Tokyo: Grant-in Aid from the Ministry of Health and Welfare of Japan 1991: 18-20
    Google Scholar
  • 69 Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin.  Am J Respir Crit Care Med . 1998;  157(6 Pt 1) 1829-1832
    CrossrefPubMedGoogle Scholar
  • 70 Nakamura H, Fujishima S, Inoue T. et al . Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection.  Eur Respir J . 1999;  13 1371-1379
    PubMedGoogle Scholar
  • 71 Mikasa K, Sawaki M, Kita E. et al . Long-term chemotherapy using erythromycin (EM) for chronic lower airway infection: effectiveness of clarithromycin in EM ineffective cases-the fourth report [in Japanese].  Kansenshogaku Zasshi . 1992;  66 1097-10104
    PubMedGoogle Scholar
  • 72 Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections.  Antimicrob Agents Chemother . 1995;  39 1688-1690
    PubMedGoogle Scholar
  • 73 Shirai T, Sato A, Chida K. Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity.  Intern Med . 1995;  34 469-474
    PubMedGoogle Scholar
  • 74 Nakata K, Taguchi Y, Kudoh S. Therapeutic guidelines for DPB [author's transl.] [in Japanese]. Annual Report on the study of diffuse lung disease in 1999. Tokyo: Grant-in Aid from the Ministry of Health and Welfare of Japan; 2000: 111
    Google Scholar
  • 75 Kudoh S. Erythromycin treatment in diffuse panbronchiolitis.  Curr Opin Pulm Med . 1998;  4 116-121
    PubMedGoogle Scholar
  • 76 Koyama H, Geddes D M. Erythromycin and diffuse panbronchiolitis.  Thorax . 1997;  52 915-918
    CrossrefPubMedGoogle Scholar
  • 77 Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease.  Pediatr Pulmonol . 2001;  31 464-473
    CrossrefPubMedGoogle Scholar
  • 78 Rubin B K, Tamaoki J. Macrolide antibiotics as biological response modifiers.  Curr Opin Investig Drugs . 2000;  1 169-172
    PubMedGoogle Scholar
  • 79 Kadota J. Antiinflammatory effects of macrolide therapy in patients with diffuse panbronchiolitis, a chronic inflammatory airway disease.  Recent Res Devel Antimicrob Agents & Chemother . 1999;  3(Pt 1) 17-38
    PubMedGoogle Scholar
  • 80 Wales D, Woodhead M. The anti-inflammatory effects of macrolides.  Thorax . 1999;  54 (suppl 2) S58-S62
    PubMedGoogle Scholar
  • 81 Yanagihara K, Kadoto J, Kohno S. Diffuse panbronchiolitis: pathophysiology and treatment mechanisms.  Int J Antimicrob Agents . 2001;  18 (suppl 1) S83-S87
    PubMedGoogle Scholar
  • 82 Labro M T. Anti-inflammatory activity of macrolides: a new therapeutic potential?.  J Antimicrob Chemother . 1998;  41 (suppl B) S37-S46
    CrossrefPubMedGoogle Scholar
  • 83 Hoyt J C, Robbins R A. Macrolide antibiotics and pulmonary inflammation.  FEMS Microbiol Lett . 2001;  205 1-7
    CrossrefPubMedGoogle Scholar
  • 84 Culic O, Erakovic V, Parnham M J. Anti-inflammatory effects of macrolide antibiotics.  Eur J Pharmacol . 2001;  429 209-229
    CrossrefPubMedGoogle Scholar
  • 85 Azuma A. Novel activity of erythromycin derivatives on inflammatory lung diseases.  Recent Res Devel Respir Crit Care Med . 2001;  1 191-207
    PubMedGoogle Scholar
  • 86 Rubin B K, Druce H, Ramirez O E, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis.  Am J Respir Crit Care Med . 1997;  155 2018-2123
    PubMedGoogle Scholar
  • 87 Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells.  Eur Respir J . 1992;  5 234-238
    PubMedGoogle Scholar
  • 88 Kondo M, Kanoh S, Tamaoki J, Shirakawa H, Miyazaki S, Nagai A. Erythromycin inhibits ATP-induced intracellular calcium responses in bovine tracheal epithelial cells.  Am J Respir Cell Mol Biol . 1998;  19 799-804
    PubMedGoogle Scholar
  • 89 Zhao D M, Xue H H, Chida K. et al . Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells.  Am J Physiol Lung Cell Mol Physiol . 2000;  278 L726-736
    PubMedGoogle Scholar
  • 90 Hojo M, Fujita I, Hamasaki Y, Miyazaki M, Miyazaki S. Erythromycin does not directly affect neutrophil functions.  Chest . 1994;  105 520-523
    PubMedGoogle Scholar
  • 91 Mitsuyama T, Hidaka K, Furuno T, Hara N. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide.  Int Arch Allergy Immunol . 1997;  114 111-115
    PubMedGoogle Scholar
  • 92 Takizawa H, Desaki M, Ohtoshi T. et al . Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells.  Am J Respir Crit Care Med . 1997;  156 266-271
    PubMedGoogle Scholar
  • 93 Desaki M, Takizawa H, Ohtoshi T. et al . Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells.  Biochem Biophys Res Commun . 2000;  267 124-128
    CrossrefPubMedGoogle Scholar
  • 94 Aoki Y, Kao P N. Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells.  Antimicrob Agents Chemother . 1999;  43 2678-2684
    PubMedGoogle Scholar
  • 95 Abe S, Nakamura H, Inoue S. et al . Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells.  Am J Respir Cell Mol Biol . 2000;  22 51-60
    PubMedGoogle Scholar
  • 96 Khair O A, Devalia J L, Abdelaziz M M, Sapsford R J, Davies R J. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells.  Eur Respir J . 1995;  8 1451-1457
    PubMedGoogle Scholar
  • 97 Keicho N, Kudoh S, Yotsumoto H, Akagawa K S. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A.  J Antibiot (Tokyo) . 1993;  46 1406-1413
    PubMedGoogle Scholar
  • 98 Morikawa K, Oseko F, Morikawa S, Iwamoto K. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro.  Antimicrob Agents Chemother . 1994;  38 2643-2647
    PubMedGoogle Scholar
  • 99 Kita E, Sawaki M, Nishikawa F. et al . Enhanced interleukin production after long-term administration of erythromycin stearate.  Pharmacology . 1990;  41 177-183
    PubMedGoogle Scholar
  • 100 Sugiyama Y, Yanagisawa K, Tominaga S I, Kitamura S. Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages.  Eur Respir J . 1999;  14 1113-1116
    CrossrefPubMedGoogle Scholar
  • 101 Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages.  J Immunol . 1999;  163 2909-2915
    PubMedGoogle Scholar
  • 102 Keicho N, Kudoh S, Yotsumoto H, Akagawa K S. Erythromycin promotes monocyte to macrophage differentiation.  J Antibiot (Tokyo) . 1994;  47 80-89
    PubMedGoogle Scholar
  • 103 Howe R A, Spencer R C. Macrolides for the treatment of Pseudomonas aeruginosa infections?.  J Antimicrob Chemother . 1997;  40 153-155
    CrossrefPubMedGoogle Scholar
  • 104 Kita E, Sawaki M, Oku D. et al . Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin.  J Antimicrob Chemother . 1991;  27 273-284
    PubMedGoogle Scholar
  • 105 Sakata K, Yajima H, Tanaka K. et al . Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro.  Am Rev Respir Dis . 1993;  148(4 Pt 1) 1061-1065
    PubMedGoogle Scholar
  • 106 Molinari G, Guzman C A, Pesce A, Schito G C. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.  J Antimicrob Chemother . 1993;  31 681-688
    PubMedGoogle Scholar
  • 107 Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides.  Am J Med . 1995;  99(6A) 26S-30S
    CrossrefPubMedGoogle Scholar
  • 108 Davies D G, Parsek M R, Pearson J P, Iglewski B H, Costerton J W, Greenberg E P. The involvement of cell-to-cell signals in the development of a bacterial biofilm.  Science . 1998;  280 295-298
    CrossrefPubMedGoogle Scholar
  • 109 Tateda K, Comte R, Pechere J C, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa Antimicrob Agents Chemother .  2001;  45 1930-1933
    CrossrefPubMedGoogle Scholar
      >